Switching from branded alendronate or risedronate to generic alendronate: effect on persistence with bisphosphonate therapy in Germany

Ziller V Schüssel K Czeche S Franzmann A Klöckner D Quinzler R Schulz M Möhrke W Hadji P

ECCEO 9-IOF, 18. - 21.03.2009, Athens, Greece.
Osteoporosis Int. 2009; 20 (Suppl. 1): S112 (Abstract P320).

Interessenskonflikte: The DAPI received financial support for this study from Procter and Gamble Pharmaceuticals; Moehrke W. employee Procter and Gamble Pharmaceuticals; Hadji P. consultant for Procter and Gamble Pharmaceuticals.

Utilizing claims data to assess persistence with antidepressants.

Persistence with basal supported oral therapy - comparison of insulin glargine versus NPH insulin.

Pharmacy refill adherence with antidepressants.

Switching from branded alendronate or risedronate to generic alendronate: effect on persistence with bisphosphonate therapy in Germany

Switching from branded alendronate or risedronate to generic alendronate: effect on persistence with bisphosphonate therapy in Germany

Beeinflusst die Umstellung von Risedronat oder Alendronat Originalprodukten auf Generika die Compliance (Persistenz)?

Der Stellenwert des DAPI in der Versorgungsforschung